Track market-moving stories before they get noisy

Prescription platform GoodRx has launched a new plan that covers a primary member and up to four dependents, including children, adult family members and pets, the company said in a Thursday (Sept. 3) press release.

GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and ​over 250 medications, and it plans to launch the program ‌as part of employer health benefits in 2027.

The program, called Companion, offers 250 generic medications for free and discounted access to telehealth, vision, dental and lab services for families paying $24.99 ​each month.

The subscription was previously only available directly to consumers on ​an individual basis. Individual Companion subscriptions cost $14.99 monthly.

CEO Wendy Barnes ⁠said the launch is meant to address affordability gaps families are facing amid ​changes to health insurance coverage.

"America’s healthcare affordability crisis is widening on both sides ​of the insurance divide," said Barnes, adding cost pressures are impacting entire households, while affordability tools often focus on individual patients. "Rising deductibles, out-of-pocket costs and coverage restrictions mean that ​having insurance no longer guarantees affordable access to care."

GoodRx says it is already ​lining up employers that want to offer the program. Those partnerships are expected to start ‌January ⁠1, 2027.

A spokesperson for GoodRx said employers can choose to subsidize the membership costs, and employees who choose to enroll would pay any remaining share.

During this year's second quarter, GoodRx's subscription revenue increased 39% year over year, and ​uptake for the Companion ​program exceeded expectations, ⁠Barnes said.

Employers expect healthcare costs to increase 9.2% in 2027, if they do not take action to mitigate expenses, ​according to the Business Group on Health.

Some employers aiming to ​manage cost ⁠increases plan to offer plans with higher deductibles, requiring workers to pay more out of pocket before insurance coverage takes effect, the Business Group on Health ⁠said.

"Pressure on ​insured consumers may be just as consequential ​as the number of people who lose coverage," said Barnes. "A person can have insurance and still face ​a prescription price they cannot afford."

GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #clamancountdown #goodrx #trumprx #wendybarnes #prescriptiondrugs #drugprices #healthcare #health #medicine #pharmacy #patients #consumer #trump #donaldtrump #donald_trump

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.

The company raised its full-year outlook, now expecting revenue of $790 million to $805 million and adjusted EBITDA of $240 million to $250 million. Chief Financial Officer Justin Fengler said the midpoint of the revenue range would bring a return to year-over-year revenue growth earlier than the company had previously anticipated.

Get GoodRx alerts:

This healthcare stock making a buzz with 160% growth“The second quarter was a strong quarter for GoodRx,” Chief Executive Officer Wendy Barnes said, citing revenue above expectations, disciplined profitability and consumer engagement across the platform.

Pharma Direct Drives Growth Pharma Direct revenue rose 76% year-over-year and 18% sequentially to $61.6 million. The business includes consumer-direct pricing and advertising solutions for pharmaceutical manufacturers.

Gene therapy: Why does it cost millions for a single treatment? Barnes said GoodRx now offers more than 135 consumer-direct pricing programs, including programs for JARDIANCE, Nurtec ODT, Otezla and Rapaflo. The company continued to support GLP-1 medication launches and expansions during the quarter, including Ozempic pill, Wegovy HD, Foundayo and Zepbound KwikPen.

GLP-1 medications remain an important contributor to Pharma Direct, management said, but executives emphasized that non-GLP-1 manufacturer partnerships also grew substantially year-over-year. Barnes said the company has been pursuing deeper partnerships with a more focused group of large pharmaceutical manufacturers and has seen its average deal size increase.

Fengler said the company now expects Pharma Direct revenue to grow more than 70% for the full year, an increase from its prior expectation of 50% to 70% growth. He added that the company has substantial visibility into its full-year Pharma Direct revenue because many bookings occur near the start of the year.

Management said it does not expect significant incremental costs to scale the Pharma Direct business, pointing to existing sales and operational infrastructure. Pharma Direct accounted for 31% of total quarterly revenue, Fengler said.

Subscriptions Expand With Companion Launch Subscription revenue increased 39% year-over-year to $28.5 million, while the number of subscription plans rose 14%. Growth was led by the company’s condition-specific offerings, particularly GoodRx for Weight Loss, as well as the May launch of GoodRx Companion.

GoodRx Companion costs $14.99 per month, or $9.99 per month under an annual plan. The offering includes 200 free generic medications, hundreds of additional medications priced below $10, online care visits and savings on dental, vision, laboratory and imaging services.

Barnes said GoodRx Gold will remain available, but Companion has become the company’s primary subscription offering because of its broader pharmacy network, expanded benefits and lower prices. The company is increasingly making subscriptions the primary call to action across its website, including its homepage and drug-price pages.

Fengler said GoodRx is still building acquisition funnels and retention programs for Companion, which launched during the quarter. The company is focused on establishing a foundation for longer-term subscription growth rather than maximizing subscription revenue in 2026, he said.

Management did not provide churn or retention figures for its condition-specific offerings or Companion. However, Fengler said subscription revenue has been growing faster than subscription plans, which the company views positively from an average-revenue-per-user perspective.

Prescription Transactions Moderate as Strategy Shifts Prescription transactions revenue was $106.4 million, in line with prior guidance. Monthly active consumers totaled 5 million, down 12% from a year earlier and down sequentially.

Fengler attributed the decline to normal seasonality in the company’s integrated savings program and GoodRx’s deliberate shift of product and marketing investments toward subscriptions. As more customers transition to subscription products, some transactions that historically would have been recorded as prescription transaction revenue will instead generate subscription revenue, management said.

Executives acknowledged that the company is evaluating whether to provide investors with different key performance indicators as its revenue mix evolves. Fengler said monthly active consumers relates only to prescription transaction revenue and is not a complete measure of business performance.

GoodRx reported more than 280 million annual site visits across its platform. Barnes said pharmaceutical companies value the company’s high-intent audience, particularly consumers who arrive with prescriptions and seek lower-cost options.

The company’s e-commerce capability is now live at nearly 6,000 pharmacies nationwide. GoodRx also became a launch partner for generics on Trump Rx in May.

Employer Pipeline and Leadership Change GoodRx said it is developing an Employer Direct pipeline, with partners expected to begin launching in the fourth quarter and first quarter. The initial focus is GLP-1 access, combining manufacturer pricing through Pharma Direct with GoodRx for Weight Loss. The company also plans to offer employers the ability to subsidize GoodRx Companion memberships for employees.

Barnes said Employer Direct is intended to complement existing insurance benefits, particularly where employers have reduced or eliminated GLP-1 coverage. She said the company has not seen explicit resistance from pharmacy benefit managers to the initiative.

The company also announced that Chris McGinnis transitioned from the chief financial officer role. Fengler, who had served as chief strategy and operations officer and has been with GoodRx for more than a decade, assumed the CFO position in addition to his existing role.

On capital allocation, Fengler said GoodRx did not repurchase shares during the quarter and that its top priority remains investing in growth initiatives, particularly Pharma Direct and subscriptions. The company may also evaluate merger-and-acquisition opportunities opportunistically, he said.

About GoodRx (NASDAQ:GDRX)GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in GoodRx Right Now?Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

For the quarter ended June 2026, GoodRx Holdings, Inc. (GDRX - Free Report) reported revenue of $200.41 million, down 1.3% over the same period last year. EPS came in at $0.08, compared to $0.09 in the year-ago quarter.

The reported revenue represents a surprise of +3.92% over the Zacks Consensus Estimate of $192.86 million. With the consensus EPS estimate being $0.08, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts.Subscription plans: 764 compared to the 726 average estimate based on two analysts.Revenue- Prescription transactions: $106.39 million versus the three-analyst average estimate of $109.31 million. The reported number represents a year-over-year change of -25.6%.Revenue- Other: $3.88 million versus the three-analyst average estimate of $3.88 million. The reported number represents a year-over-year change of -15%.Revenue- Pharma direct: $61.63 million compared to the $55.4 million average estimate based on three analysts. The reported number represents a change of +76.2% year over year.Revenue- Subscription: $28.51 million versus $25.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +39.3% change.View all Key Company Metrics for GoodRx here>>>

Shares of GoodRx have returned +10.2% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 6, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's bus.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

One company value investors might notice is GoodRx (GDRX - Free Report) . GDRX is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 9.21, while its industry has an average P/E of 16.38. Over the last 12 months, GDRX's Forward P/E has been as high as 17.97 and as low as 8.01, with a median of 11.31.

Investors should also note that GDRX holds a PEG ratio of 0.81. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. GDRX's industry currently sports an average PEG of 1.33. GDRX's PEG has been as high as 1.49 and as low as 0.64, with a median of 1.02, all within the past year.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. GDRX has a P/S ratio of 1.32. This compares to its industry's average P/S of 1.47.

These are only a few of the key metrics included in GoodRx's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, GDRX looks like an impressive value stock at the moment.

Nutex Health (NASDAQ: NUTX - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Nutex Health and GoodRx's

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business o.

Key Takeaways Hims & Hers is moving care online with telehealth consults, digital prescriptions and home fulfillment.HIMS partnered with Novo Nordisk to offer FDA-approved GLP-1s in multiple formats at more affordable prices.HIMS added multi-cancer early detection testing and a Labs platform, while expanding into Canada and Europe. Hims & Hers Health, Inc. (HIMS - Free Report) is fundamentally built around expanding access to healthcare by shifting traditionally fragmented, in-person experiences into a more seamless digital model. Its platform connects consumers to licensed providers, enabling telehealth consultations, digital prescriptions and online fulfillment, all designed to make care faster, and more convenient and affordable. By integrating these capabilities, HIMS aims to reduce longstanding barriers such as stigma, cost and limited provider availability, while delivering personalized care across a wide range of conditions.

Recent developments reinforce this access-driven strategy. Hims & Hers has continued to broaden the availability of treatments by partnering with Novo Nordisk to offer FDA-approved GLP-1 medications at more affordable prices and through multiple delivery formats, simplifying access for eligible patients. At the same time, it has expanded proactive care through new offerings such as multi-cancer early detection testing and its Labs platform, both of which are designed to make advanced diagnostics more accessible and actionable for everyday consumers.

Geographic expansion has further extended this mission. Through acquisitions and market entries, Hims & Hers is scaling its digital-first model globally, including in Canada and Europe, with a focus on bringing affordable, personalized care to populations where access has historically been limited. Together, these initiatives reflect a consistent effort to democratize healthcare — making high-quality, personalized care more accessible across conditions, formats and geographies.

Hims & Hers is scheduled to report first-quarter 2026 results on May 11, after the closing bell.

GDRX and TDOC Expanding Digital Healthcare AccessGoodRx Holdings, Inc. (GDRX - Free Report) is advancing digital-first healthcare access by simplifying how consumers find, afford and receive treatments. GDRX has expanded condition-specific subscriptions, including services for hair loss and erectile dysfunction that combine virtual consultations, prescriptions and home delivery into a single streamlined experience, reducing barriers such as cost and inconvenience. At the same time, GoodRx continues to scale affordability through partnerships and pricing innovations. GoodRx enables access to high-cost therapies like GLP-1 treatments with transparent self-pay pricing, while also integrating savings directly at the pharmacy counter through programs like RxSmartSaver.

Teladoc Health, Inc. (TDOC - Free Report) is advancing digital-first healthcare access by delivering comprehensive virtual care across physical and mental health needs through its Integrated Care and BetterHelp platforms. Teladoc Health connects patients, providers and systems to enable 24/7 access to services spanning preventive, primary, chronic and mental healthcare, improving outcomes while lowering costs. Teladoc Health recently enhanced its 24/7 Care service to treat a broader range of conditions, integrate specialist input and streamline referrals, further expanding access and care continuity through its technology-driven ecosystem.

HIMS’ Price Performance, Valuation and EstimatesShares of Hims & Hers have lost 14.1% year to date compared with the industry’s decline of 21.8%.

Image Source: Zacks Investment Research

HIMS’ forward 12-month P/S of 2.1X is lower than the industry’s average of 3.4X and its five-year median of 2.6X. It has a Value Score of C.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 5.7% improvement compared with 2025.

Image Source: Zacks Investment Research

Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.

For the quarter ended March 2026, GoodRx Holdings, Inc. (GDRX - Free Report) reported revenue of $194.01 million, down 4.4% over the same period last year. EPS came in at $0.07, compared to $0.09 in the year-ago quarter.

The reported revenue represents a surprise of +7.73% over the Zacks Consensus Estimate of $180.09 million. With the consensus EPS estimate being $0.07, the EPS surprise was -5.41%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts.Subscription plans: 717 versus the two-analyst average estimate of 679.Revenue- Prescription transactions: $113.69 million versus $114.73 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -23.7% change.Revenue- Other: $3.69 million versus the three-analyst average estimate of $3.99 million. The reported number represents a year-over-year change of -15.8%.Revenue- Pharma direct: $52.23 million versus the three-analyst average estimate of $40.07 million. The reported number represents a year-over-year change of +82.3%.Revenue- Subscription: $24.39 million versus $21.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.View all Key Company Metrics for GoodRx here>>>

Shares of GoodRx have returned +24.9% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

© Inna Kot / Shutterstock.com

You turn 65, sign up for Medicare, and a wall of mail arrives pushing standalone Part D drug plans. The default move for decades has been to pick one and forget it. For 2026, that default deserves a fresh look. The Inflation Reduction Act fully kicks in this year, premiums and surcharges shift, and bundled Medicare Advantage plans now compete aggressively for the same enrollees.

Part D still matters. The late enrollment penalty is permanent and often misunderstood. The real question is which drug coverage path fits, especially if you take a few medications today.

The 2026 numbers that frame the decision Part D national base premium of $36.78 per month — This is the benchmark figure CMS uses to calculate late enrollment penalties and IRMAA surcharges. Actual plan premiums vary by carrier and state, but the base premium drives the math behind every surcharge calculation. Maximum Part D deductible of $590 — Plans can charge less, but no standalone drug plan can require you to pay more than this before cost-sharing kicks in. Many low-premium plans hit this cap, so factor it into total-cost comparisons rather than focusing solely on the monthly premium. New annual out-of-pocket cap on prescriptions of $2,000 — This is the headline change from the Inflation Reduction Act. Once your true out-of-pocket drug spending reaches the cap, you pay nothing more for covered medications for the rest of the year, eliminating the old catastrophic coinsurance phase. IRMAA surcharge range for higher-income retirees of $14.50 to $91.00 per month — Retirees with modified adjusted gross income above the thresholds pay this surcharge on top of their plan premium. Because IRMAA is added regardless of which Part D plan you choose, high earners benefit most from selecting the lowest-premium compliant plan. For a retiree paying around $42 a month in premiums for 25 years, the total outlay reaches roughly $12,600, which can exceed what they ever recoup at the pharmacy counter.

Why did the math change this year? The single biggest shift: the $2,000 annual out-of-pocket cap and the elimination of the catastrophic coinsurance phase. Before this rule, a cancer drug or specialty medication could expose a retiree to five-figure annual costs. Now the worst-case pharmacy bill is capped. Premiums now fund routine cost-sharing on prescriptions you actually fill, with catastrophic risk already capped.

For a retiree on no medications, the expected value of a richer plan drops sharply. For someone on three or four maintenance drugs, the cap is still useful, but the premium gap between the cheapest plan and a mid-tier plan rarely pays off.

The trap on the other side is the late enrollment penalty. Skip Part D for five years and the Social Security Administration adds about $22 a month to your premium for life. That is roughly $264 a year, every year, forever. The penalty math alone is why a placeholder plan beats no plan.

Three reasons to reconsider a standalone plan The cheapest compliant plan often wins. If you take few or no drugs, Part D’s role in 2026 is mainly to avoid the lifetime penalty and give you access to the $2,000 cap if your health changes. Paying for a richer formulary you don’t use is a drag. The lowest-premium plan in your state, paired with GoodRx (NASDAQ: GDRX | GDRX Price Prediction) or Costco (NASDAQ: COST) cash pricing for cheap generics, frequently beats a mid-tier plan on total spend. A Medicare Advantage drug plan (MA-PD) may already include it. If you are weighing Original Medicare plus Medigap plus standalone Part D against an MA-PD bundle, the bundle combines drug coverage into a single premium. The tradeoff is network restrictions and prior authorization. For healthy retirees who value a single bill and lower upfront cost, MA-PD removes the standalone Part D decision entirely. For those who travel often or want any-doctor access, Original Medicare plus standalone Part D still wins. IRMAA surcharges punish high earners twice. A retiree in the top income bands pays the Part B surcharge plus a Part D IRMAA of up to $91 a month, pushing annual Part D cost toward $1,533 in premiums alone before a single prescription is filled. If your modified AGI puts you in IRMAA territory, the cheapest base plan limits the surcharge damage, since IRMAA is added on top regardless of which plan you choose. What to do during open enrollment Evaluate your actual medication list and your projected income two years out, since IRMAA looks back. If you have creditable drug coverage through a former employer or a spouse’s active plan, document it. That coverage defers the penalty clock, and losing it later triggers a special enrollment window without lifetime surcharges.

The common, costly mistake is autopilot. Plans change formularies and premiums every year. Re-shop annually on Medicare.gov’s plan finder using your current drug list. Five minutes of effort routinely saves several hundred dollars, and it is the only way to ensure the cap, the premium, and your prescriptions still line up.

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion turns the pricing capabilities, retail pharmacy relationships, and consumer experience GoodRx has built over more than a decade into a membership designed to make everyday care more affordable and predictable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527868807/en/

“GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today,” said Wendy Barnes, President and CEO of GoodRx. “As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value. Companion meets that demand while advancing our strategy to build deeper, more recurring consumer relationships across a growing portfolio of subscription offerings. This is where we believe the market is headed, and where we believe GoodRx is uniquely positioned to lead.”

One Membership. More Ways to Save.

Companion gives consumers a more comprehensive way to save on routine healthcare, combining lower discounted cash prices on prescriptions with more affordable access to the care and services they use throughout the year. Companion is particularly beneficial to patients managing chronic conditions, those who are taking multiple medications, or those with health insurance coverage limitations.

Benefits include:

Prescription savings: More than 200 common generic medications for free, with hundreds more for less than $10, available at nearly every pharmacy nationwide Online care: $19 telehealth visits on GoodRx Care for common needs such as UTIs, skin care, flu, and other routine conditions Dental care: Savings on cleanings, exams, X-rays, crowns, and other dental services Vision care: Savings on eye exams, glasses, contact lenses, and laser eye surgery Lab and imaging services: Significant savings on common lab and imaging services such as MRIs, CT scans, ultrasounds, comprehensive wellness labs, and hormone panels A Broader Subscription Model for a Changing Healthcare Market

The launch of Companion advances GoodRx’s subscription strategy by adding a broader membership offering alongside its condition-focused offerings for weight loss, erectile dysfunction, and hair loss. It creates another recurring revenue stream, gives GoodRx a more continuous way to engage consumers beyond individual prescription transactions, and strengthens the company’s move toward a more diversified membership model with favorable pharmacy economics.

To learn more, visit: www.goodrx.com/companion

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits, pricing and value of GoodRx Companion and related pricing; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527868807/en/